发布: 2020年08月20日第10卷第16期 DOI: 10.21769/BioProtoc.3725 浏览次数: 4418
评审: Steven BoeynaemsIndranil MalikDonya Pakravan
Abstract
The study of RNA-binding proteins (RBP) offers insight into the mechanisms of pathologic protein aggregation in neurodegenerative diseases. We developed a protocol for purifying an RBP FUS and a nuclear import receptor (NIR) Kapβ2 and testing the ability of Kapβ2 to mitigate FUS aggregation and liquid-liquid phase separation.
Keywords: FUS (FUS)Background
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diseases characterized by the mislocalization and aggregation of several RNA-binding proteins (RBP) (Mackenzie et al., 2010; Da Cruz and Cleveland, 2011; King et al., 2012). One of these proteins is FUS (Fused in Sarcoma), a nuclear protein mislocalizes in the cytoplasm of neurons in ALS/FTD patients, where it undergoes liquid-liquid phase transition followed by aberrant phase transition to form insoluble aggregates (Altmeyer et al., 2015; Burke et al., 2015; Lin et al., 2015; Molliex et al., 2015; Murakami et al., 2015; Patel et al., 2015) (Figure 1). Karyopherin-β2 (Kapβ2), a nuclear import receptor (NIR), has been established as a chaperone and disaggregase of proteins with PY-nuclear localization sequences (NLS), such as FUS (Guo et al., 2018; Hofweber et al., 2018; Yoshizawa, et al., 2018). The following protocol was developed to test the ability of Kapβ2 to inhibit and reverse FUS aggregation and phase separation ex vivo (Guo et al., 2018).
Figure 1. Aberrant phase transition of FUS (10 μM) leads to the formation of fibrillar hydrogel. A. Domain architecture of FUS. B. DIC images show that FUS undergoes reversible liquid-liquid phase transition to form liquid droplets followed by aberrant phase transition to form hydrogels. Scale bar: 10 μm.
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2020 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Robinson, E., Shorter, J. and Guo, L. (2020). Karyopherin-β2 Inhibits and Reverses Aggregation and Liquid-liquid Phase Separation of the ALS/FTD-Associated Protein FUS. Bio-protocol 10(16): e3725. DOI: 10.21769/BioProtoc.3725.
分类
神经科学 > 神经系统疾病 > 神经退行性病变
生物化学 > 蛋白质 > 自组装
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link